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Abstract
Over the last decade, there has been a significant rise in deaths due to drug
overdoses involving opioids. Opioids are highly addictive due to the
rewarding effects they produce in the brain and body. Methadone, which is
administered in a clinic, and buprenorphine, which can be taken at home,
are the two leading treatment options for opioid use disorder. This review
analyzes the efficacy of treatment with buprenorphine, compared to
methadone, in remission of opioid use disorder.

Introduction
Overview
❖
In 2018, 10.3 million people misused prescription opioids, which
led to the death of roughly 130 people per day.
❖
Opioids work by releasing dopamine in the brain.
Treatment
❖
Methadone is a full agonist, and must be administered through
an IV in a clinic
❖
Buprenorphine is a partial agonist and can be taken orally at
home
❖
Both cause euphoria, however buprenorphine has less potential
for abuse due to a low ceiling for the euphoric effect.

Methods

Results

Discussion
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Literature search
❖

❖
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Performed on October 23, 2019 using
➢
Pub Med
➢
Academic Search ultimate
Search terms
➢
Buprenorphine AND methadone AND adults
Inclusion criteria
➢
Clinical trials, humans, adult 19+, published within the last 5
years, therapeutic use
Exclusion criteria
➢
Systemic reviews, meta-analysis, prenatal effects, drug
interactions, financial effects
This narrowed down the search to a total of seven articles

Key: SM = Methadone showed significant difference, SB = buprenorphine showed significant difference (Increased
retention, reduction in mortality, reduction of illicit drug use, reduction of opioid use in general); NS = No significant
difference between both drugs; NA = Not applicable

Overview
❖ Four of the seven studies found methadone to be significantly more
effective in increasing treatment retention times.
❖ Four of the seven studies also found that between the two treatment
options, there was no significant reduction in opioid use in general.
❖ While methadone did induce a longer retention of treatment, these results
indicate that since neither drug is more effective in the reduction of opioid
usage in general, there may be other social determinants influencing time
retained in treatment.
❖ It is clear that while buprenorphine may have earlier drop-out rates,
eventually the retention curves stabilize and become comparable to that
of methadone. Many of the studies have suggested that social
determinants, and not the drug itself, are influencing the earlier drop-out
rate of buprenorphine.
Limitations
❖ Overall, small sample sizes
❖ Minimal follow-up after the trial
❖ Relatively short length of the study
Future Research
❖ Larger sample sizes
❖ Analyze socioeconomic effects on receiving adequate treatment
❖ Ways to improve early drop off rates

Conclusion
Buprenorphine and methadone have both been prescribed as
treatment of opioid withdrawal, but little evidence has been
conducted to evaluate which drug is more beneficial. Research, as of
today, has shown methadone increases time maintained in
treatment, but not an overall significant decrease in opioid reduction.

The studies were limited by small sample size, short lengths and
minimal follow-up after the study. Future research is necessary to
determine what other factors are influencing the differences in
treatment retention. With buprenorphine having a higher incidence of
dropouts early on in the treatment, it is crucial to understand factors
contributing to this difference.

